Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Rucaparib (Primary)
- Indications Adenocarcinoma; Biliary cancer; Gallbladder cancer
- Focus Therapeutic Use
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 16 May 2019 According to a Clovis Oncology media release, data from this trial will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 to June 4 in Chicago.
- 07 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Feb 2019.